Conv. Plasma
Nigella Sativa

All aspirin studies
Meta analysis
study COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Aspirin for COVID-19  Santoro et al.  LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 7,824 patients in multiple countries (Jan - May 2020) Lower mortality with aspirin (p=0.017) Santoro et al., J. the American Heart .., Jun 2022 Favors aspirin Favors control

Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry

Santoro et al., Journal of the American Heart Association, doi:10.1161/JAHA.121.024530
Jun 2022  
  Source   PDF   All   Meta
Aspirin for COVID-19
24th treatment shown to reduce risk in August 2021
*, now known with p = 0.000087 from 73 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
HOPE-COVID-19 PSM retrospective 7,824 patients, comparing prophylactic anticoagulation with and without additional treatment with aspirin in hospitalized patients, showing lower mortality with aspirin treatment.
risk of death, 38.0% lower, HR 0.62, p = 0.02, treatment 360, control 2,949.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Santoro et al., 22 Jun 2022, retrospective, propensity score matching, multivariable, multiple countries, peer-reviewed, 31 authors, study period 16 January, 2020 - 30 May, 2020. Contact:
This PaperAspirinAll
Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID‐19: A Propensity Score‐Matched Cohort Analysis of the HOPE‐COVID‐19 Registry
Francesco Santoro, Ivan J Núñez‐gil, MD Enrica Vitale, María C Viana‐llamas, MD Rodolfo Romero, Charbel Maroun Eid, MD Gisela Feltes Guzman, Victor Manuel Becerra‐muñoz, Inmaculada Fernández Rozas, MD Aitor Uribarri, Emilio Alfonso‐rodriguez, Marcos García Aguado, MD Jia Huang, Alex Fernando Castro Mejía, Juan Fortunato Garcia Prieto, MD Javier Elola, Fabrizio Ugo, Enrico Cerrato, Jaime Signes‐costa, Sergio Raposeiras Roubin, Jorge Luis Jativa Mendez, Carolina Espejo Paeres, Alvaro López Masjuan, Francisco Marin, MD Federico Guerra, Ibrahim El‐battrawy, MD Bernardo Cortese, Harish Ramakrishna, Julian Perez‐villacastín, Antonio Fernandez‐ortiz, MD Natale Daniele Brunetti
Journal of the American Heart Association, doi:10.1161/jaha.121.024530
BACKGROUND: COVID-19 is an infectious illness, featured by an increased risk of thromboembolism. However, no standard antithrombotic therapy is currently recommended for patients hospitalized with COVID-19. The aim of this study was to evaluate safety and efficacy of additional therapy with aspirin over prophylactic anticoagulation (PAC) in patients hospitalized with COVID-19 and its impact on survival. METHODS AND RESULTS: A total of 8168 patients hospitalized for COVID-19 were enrolled in a multicenter-international prospective registry (HOPE COVID-19). Clinical data and in-hospital complications, including mortality, were recorded. Study population included patients treated with PAC or with PAC and aspirin. A comparison of clinical outcomes between patients treated with PAC versus PAC and aspirin was performed using an adjusted analysis with propensity score matching. Of 7824 patients with complete data, 360 (4.6%) received PAC and aspirin and 2949 (37.6%) PAC. Propensity-score matching yielded 298 patients from each group. In the propensity score-matched population, cumulative incidence of in-hospital mortality was lower in patients treated with PAC and aspirin versus PAC (15% versus 21%, Log Rank P=0.01). At multivariable analysis in propensity matched population of patients with COVID-19, including age, sex, hypertension, diabetes, kidney failure, and invasive ventilation, aspirin treatment was associated with lower risk of in-hospital mortality (hazard ratio [HR], 0.62; [95% CI 0.42-0.92], P=0.018). CONCLUSIONS: Combination PAC and aspirin was associated with lower mortality risk among patients hospitalized with COVID-19 in a propensity score matched population compared to PAC alone.
ARTICLE INFORMATION Received March 9, 2022; accepted April 28, 2022. Affiliations Sources of Funding This work was supported by an unconditioned grant (Fundacion Interhospitalaria para la Investigacion Cardiovascular [FIC] Madrid, Spain). This nonprofit institution had no role in the study design; in the collection, analysis, interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication. This paper has been published with the financial support of the Dept. of Medical and Surgical Sciences of the University of Foggia, Foggia, Italy. Disclosures None. Supplemental Material Tables S1-S3 SUPPLEMENTAL MATERIAL
Alhazzani, Møller, Arabi, Loeb, Gong et al., Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19), Crit Care Med, doi:10.1097/CCM.0000000000004363
Buijsers, Yanginlar, Maciej-Hulme, De Mast, Der Vlag, Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients, EBioMedicine, doi:10.1016/j.ebiom.2020.102969
Carlo, None
Clinico, Carlos, None
Florêncio, Tenório, Júnior, Lima, Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease, Rev Soc Bras Med Trop, doi:10.1590/0037-8682-0472-2020
Goligher, Bradbury, Mcverry, Lawler, Berger et al., REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators. Therapeutic anticoagulation in critically ill patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2103417
Henn, Slupsky, Gräfe, Anagnostopoulos, Förster et al., CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, doi:10.1038/35393
Imib-Arrixaca, Cibercv ; (f, Cardiology and Arrhythmology Clinic, Ospedali Riuniti "Umberto I -Lancisi -Salesi
Infermi Hospital, None
Kopp, Ghosh, Inhibition of NF-kappa B by sodium salicylate and aspirin, Science, doi:10.1126/science.8052854
Lawler, Goligher, Berger, Neal, Mcverry et al., The ATTACC, ACTIV-4a, and REMAP-CAP Investigators* Therapeutic anticoagulation in non-critically ill patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2105911
Lopes, De Barros E Silva, Furtado, Macedo, Bronhara et al., Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated Ddimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial, Lancet, doi:10.1016/S0140-6736(21)01203-4
Malas, Naazie, Elsayed, Mathlouthi, Marmor et al., Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and metaanalysis, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100639
Mazloomzadeh, Khaleghparast, Ghadrdoost, Mousavizadeh, Baay et al., Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial, JAMA, doi:10.1001/jama.2021.4152
Mazzeffi, Chow, Tanaka, COVID-19 associated hypercoagulability: manifestations, mechanisms, and management, Shock, doi:10.1097/SHK.0000000000001660
Mei, Luo, Hu, Thrombocytopenia and thrombosis in hospitalized patients with COVID-19, J Hematol Oncol, doi:10.1186/s13045-020-01003-z
Núñez-Gil, Estrada, Fernández-Pérez, Feltes, Vedia et al., Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design, Contemp Clin Trials Commun, doi:10.1016/j.conctc.2020.100654
Pavoni, Gianesello, Pazzi, Stera, Meconi et al., Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: a call to action, Thromb Res, doi:10.1016/j.thromres.2020.09.013
Pellegrini, Kawakami, Guagliumi, Sakamoto, Kawai et al., Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study, Circulation, doi:10.1161/CIRCULATIONAHA.120.051828
Rapkiewicz, Mai, Carsons, Pittaluga, Kleiner et al., Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100434
Santoro, Nuñez-Gil, Vitale, Viana-Llamas, Martinez et al., Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry, Heart, doi:10.1136/heartjnl-2021-319552
Santoro, Núñez-Gil, Viana-Llamas, Eid, Romero et al., Anticoagulation therapy in patients with coronavirus disease 2019: results from a multicenter international prospective registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19]), Crit Care Med, doi:10.1161/CIRCULATIONAHA.110.009449
Xie, Xu, Bowe, Al-Aly, Long-term cardiovascular outcomes of COVID-19, Nat Med, doi:10.1038/s41591-022-01689-3
Zhang, Penninger, Li, Zhong, Slutsky, Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med, doi:10.1007/s00134-020-05985-9
Zhu, Zhang, Li, Yang, Song et al., A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop